CPT® Code 81293

MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants

The CPT® Code 81293 pertains to the molecular genetic testing of the MLH1 gene, specifically focusing on known familial variants associated with hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome. This testing is crucial for identifying specific mutations within the MLH1 gene that significantly increase an individual's risk of developing colorectal cancer and other related malignancies. The MLH1 gene, located on chromosome 3, plays a vital role in encoding proteins responsible for DNA repair. When mutations occur in this gene, they can either prevent the production of the MLH1 protein or alter its structure, rendering it ineffective in repairing DNA errors. Over time, these unrepaired errors can accumulate, leading to uncontrolled cell proliferation and the formation of tumors. HNPCC is the most prevalent cancer type linked to MLH1 mutations, but the implications of these mutations extend beyond colorectal cancer. Individuals with MLH1 mutations may also face an increased risk of developing cancers in various organs, including the endometrium, ovaries, prostate, stomach, small intestine, liver, gallbladder duct, upper urinary tract, brain, and skin. The identification of these mutations is particularly important for family members of affected individuals, as they may also carry the same genetic risk. The testing process involves analyzing known familial variants to assess the likelihood of these mutations being present in relatives, thereby aiding in the determination of their cancer risk. This targeted approach to genetic testing is essential for effective cancer risk management and prevention strategies within families affected by Lynch syndrome.